רווח למניה בשנים עשר החודשים האחרונים: BeiGene Ltd. (BGNE)

BeiGene, Ltd. (BGNE) faces critical geopolitical risk due to trade conflicts between the US and China. The TTM fundamental earnings per share on the GURU.Markets daily price chart demonstrates current resilience, where 7.85 describes the current status of the metric. Revenues are based on Brukinsa sales and royalties, while diversification through global clinical trials expands the company's market potential.
פילוחים אנליטיים ודוחות נתונים של חברת BeOne Medicines (BGNE)

The market views BeiGene, Ltd. (BGNE) as a promising asset with high scaling potential. The EPS TTM metric aggregates net income over the last four quarters, allocating it per share to determine the actual return on equity. By analyzing this TTM earnings per share chart, an investor can see the commercialization efficiency of drugs in the US and China. The growth of this indicator confirms the company's ability to convert market expansion into net income. This tool characterizes the shares as a high-tech biopharmaceutical asset.